IMPACT OF COVID-19 ON INFLAMMATORY BOWEL DISEASE: COURSE AND OUTCOME
Introduction. Coronavirus infection is an acute viral disease with a primary lesion of the upper respiratory tract, caused by an RNA-virus of the Betacoronavirus genus of the Coronaviridae family. The course of a viral infection varies from asymptomatic to a wide range of clinical manifestations, including fever, chills, gastrointestinal manifestations, pneumonia, respiratory distress, and death.
Ulcerative colitis (UC) and Crohn's disease (CD) are chronic immune-mediated diseases with intestinal and systemic symptoms, which are based on an impairment of the intestinal microbiota and dysregulation of the immune system in genetically predisposed individuals. In the Kazakh population, risk factors also include irregular food intake (p=0.043; OR=3.61 [95% CI: 1.04–12.51]), consumption of fish and seafood (p=0.000; OR= 15.77 [95% CI: 4.56-54.59]), consumption of frozen processed foods (p = 0.018; OR = 4.62 [95% CI: 1.3-16.4]), diet based on meat dishes (p=0.029; OR=3.2 [95% CI: 1.13-9.2]), use of NSAIDs other than aspirin (p=0.031; OR=3.79 [1.13-12.69 ]) and smoking (p=0.008; OR=4.93 [95% CI: 1.52-15.98]).
The suppression of the immune response is associated with the risk of infection with viral or bacterial pathogens, including potentially the SARS-CoV-2 virus. On the other hand, SARS-CoV-2 infection as a potential trigger factor for de novo occurrence of inflammatory bowel disease is currently being discussed.
The aim of this study was to assess the characteristics of the course of COVID-19 during the treatment of inflammatory bowel diseases (IBD), risk factors and outcomes of COVID-19, as well as the activity of IBD before and after a coronavirus infection.
Materials and methods. A longitudinal descriptive study included 158 patients with IBD who applied on an outpatient basis (including via remote consultation) or inpatient with SARS-Cov2 or COVID-19 infection in the academic centers of Almaty (Kazakhstan) n=54 and St. Petersburg (Russia), n= 104. The observation period was from May 2020 to May 2022.
The median and interquartile range were used to describe quantitative data (age), and absolute frequencies and percentages were used for qualitative data. The Mann-Whitney U-test was used for intergroup comparison of quantitative data (age), for the remaining indicators, the likelihood ratio test (Likehood ratio test), and in the case of 2X2 tables, Fisher's exact test.
Results. There was no association between IBD type/activity or drugs taken and the severity of COVID-19. However, the severity of COVID-19 affected the activity of IBD. We`ve identified the same risk factors for the development of a more severe course of COVID-19 were as in the world literature: cardiovascular pathology, arterial hypertension and chronic liver pathology.
Conclusion. Thus, inflammatory bowel disease and current therapy do not affect the risk of SARS-Cov-2 infection and/or the severity of COVID-19, while infection associated with severe COVID-19 affects the activity or outcomes of IBD.
Аinash S. Tanabayeva1, https://orcid.org/0000-0003-3228-9796
Irina V. Gubonina2, https://orcid.org/0000-0002-6302-7767
Vladimir B. Grinevich2, https://orcid.org/0000-0002-1095-8787
Timur V. Kolodin2,
Zauresh K. Zhumadilova6,
Aizhan Zhanabayeva3, https://orcid.org/0000-0001-6852-9179
Zukhra Kh. Agzamova,3, https://orcid.org/0000-0002-4311-9314
Alfiya M. Amirova1, https://orcid.org/0000-0002-4778-5488
Aliya E. Ualieva4, https://orcid.org/0000-0002-4776-1988
Alexander V. Nersesov1, https://orcid.org/0000-0002-8601-3966
Jamilya A. Kaibullayeva1,5, https://orcid.org/0000-0002-0783-4441
1 Asfendiyarov kazakh national medical university, Almaty c., Republic of Kazakhstan;
2 Military Medical Academy named after S.M. Kirov, St. Petersburg c., Russian Federation;
3 Research Institute of cardiology and Internal diseases, Almaty c., Republic of Kazakhstan;
4 Al-Farabi kazakh national university, Almaty c., Republic of Kazakhstan;
5 Gastrohepatocenter, Almaty c., Republic of Kazakhstan;
6 NCJSC "Semey Medical University", Semey c., Republic of Kazakhstan.
1. Ananthakrishnan A.N., McGinley E.L. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis 2013;7:107–112.
2. Brenner E.J., Ungaro R.C., et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology 2020; 159:481–491.
3. Cai Z., Wang S., Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front. Med. 2021, 8:765474. doi: 10.3389/fmed.2021.765474
4. Chena F., Chenb W., Chen J. et al. Clinical features and risk factors of COVID-19-associated liver injury and function: A retrospective analysis of 830 cases. Annals of hepatology, 21 (2021) 100267.
5. Clift A.K., Coupland C.A.C., Keogh R.H. et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study // BMJ. 2020; 371:m3731 doi:10.1136/bmj.m3731
6. Coronavirus infection COVID-19 in adults (6th edition), Clinical protocol 166, July 25, 2022, Republic of Kazakhstan.
7. СOVID-19 Map. Johns Hopkins Coronavirus Resource Center. Accessed December 17, 2020.
8. Donoghue M., Hsieh F., Baronas E., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 // Circ Res. 2000 Sep 1;87(5):E1-9. doi: 10.1161/01.res.87.5.e1.
9. Garg M., Burrell L.M. et al. Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: a pilot study // J Renin Angiotensin Aldosterone Syst 2015;16:559–69.
10. Garg M., Royce S.G., Tikellis C., et al. Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target? // Gut 2020;69:841–51.
11. Hashimoto T., Perlot T., Rehman A., et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation // Nature 2012;487:477–81.
12. Keidar S., Kaplan M., Gamliel-Lazarovich A. ACE2 of the heart: From angiotensin I to angiotensin (1-7) // Cardiovasc Res. 2007 Feb 1;73(3):463-9. Epub 2006 Sep 19. PMID: 17049503.
13. Kirchgesner J., Lemaitre M., Carrat F., et al. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases // Gastroenterology 2018; 155:337–346.e10.
14. Lin Simeng, Lau Louis H.S., Chanchlani Neil et al. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic // Gut 2022;71:1426–1439. doi:10.1136/gutjnl-2021-326784
15. Long M.D., Martin C., Sandler R.S., et al. Increased risk of pneumonia among patients with inflammatory bowel disease // Am J Gastroenterol 2013;108:240–248.
16. Ma C., Lee J.K., Mitra A.R., et al. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease // Aliment Pharmacol Ther 2019;50:5–23.
17. Macaluso F.S., Orlando A. COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data // Dig Liver Dis. 2020 Nov;52(11):1222-1227. doi: 10.1016/j.dld.2020.09.002. Epub 2020 Sep 6. PMID: 32928672; PMCID: PMC7474894.
18. Onder G., Rezza G., Brusaferro S.. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy // JAMA. 2020 May 12;323(18):1775-1776. doi: 10.1001/jama.2020.4683. Erratum in: JAMA. 2020 Apr 28;323(16):1619. PMID: 32203977.
19. Rahman A., Sathi N.J. Risk factors of the severity of COVID-19: A meta-analysis // Int J Clin Pract. 2021 Jul;75(7):e13916
20. Ramos G.P., Papadakis K.A. Mechanisms of Disease: Inflammatory Bowel Diseases // Mayo Clin Proc. 2019 Jan;94(1):155-165. doi: 10.1016/j.mayocp.2018.09.013. PMID: 30611442; PMCID: PMC6386158.
21. Singh S., Khan A., et al. Risk of Severe Coronavirus Disease 2019 in Patients With Inflammatory Bowel Disease in the United States: A Multicenter Research Network Study // Gastroenterology. 2020 Oct;159(4):1575-1578.e4. doi: 10.1053/j.gastro.2020.06.003. Epub 2020 Jun 6. PMID: 32522507; PMCID: PMC7702184.
22. Tanabayeva A.S. et all. Clinical and epidemiological features of COVID-19 in inflammatory bowel diseases in the Republic of Kazakhstan, poster within the framework of the Central Asian Gastroweek, http://kasl.kz/event/poster?id=17688&article=33977
23. Tinsley A., Williams E., Liu G., et al. The incidence of influenza and influenza-related complications in inflammatory bowel disease patients across the United States: 1833 // Am J Gastroenterol 2013:108.
24. Tripathi Kartikeya, Brewer Gala Godoy, Nguyen Minh Thu et al. COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis // Inflamm Bowel Dis. 2021 Oct 27 : izab236.
25. Tursi A., Lopetuso L.R., Vetrone L.M. et al. SARS-CoV-2 infection as a potential trigger factor for de novo occurrence of inflammatory bowel disease // Eur J Gastroenterol Hepatol. 2022 Aug; 34(8): 883–884.
26. Ualiyeva A., Oshibayeva A., Kaibullayeva J. Determination of environmental factors associated with inflammatory bowel disease in Kazakhstan: a case-control study // Nauka i Zdravookhranenie [Science & Healthcare]. 2020, (Vol.22) 4, pp. 97-104. doi 10.34689/SH.2020.22.4.010
27. Ungaro R.C., Brenner E.J., et al. Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) Research Group. Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of Over 6,000 Patients from an International Registry // Gastroenterology 2022; 162:316–319
Количество просмотров: 289
Категория статей:
Оригинальные исследования
Библиографическая ссылка
Tanabayeva А.S., Gubonina I.V., Grinevich V.B., Kolodin T.V., Zhumadilova Z.K., Zhanabayeva A., Agzamova Z.Kh., Amirova A.M., Ualieva A.E., Nersesov A.V., Kaibullayeva Ja.A. Impact of COVID-19 on inflammatory bowel disease: course and outcome // Nauka i Zdravookhranenie [Science & Healthcare]. 2022, (Vol.24) 4, pp. 12-18. doi 10.34689/SH.2022.24.4.002Похожие публикации:
МЕХАНИКАЛЫҚ САРҒАЮ ОПЕРАЦИЯСЫ КЕЗІНДЕ КОАГУЛОПАТИЯЛЫҚ ҚАН КЕТУДІҢ АЛДЫН АЛУ ӘДІСІ
ОПТИМИЗАЦИЯ РЕЗУЛЬТАТОВ АУТОДЕРМОПЛАСТИКИ ПРИ ЛЕЧЕНИИ ГРАНУЛИРУЮЩИХ ГНОЙНЫХ РАН
BASICS OF REHABILITATION OF CHILDREN AFTER OPERATIONS ON THE COLON AND ANORECTAL AREA
HEALTH INDICATORS OF FIRST-YEAR-OF-LIFE CHILDREN IN THE REPUBLIC OF KAZAKHSTAN FOR 2013-2022
ОЦЕНКА УДОВЛЕТВОРЕННОСТИ ТРУДОВОЙ ДЕЯТЕЛЬНОСТЬЮ ВРАЧЕЙ АНЕСТЕЗИОЛОГОВ-РЕАНИМАТОЛОГОВ ГОРОДА АСТАНА